Literature DB >> 17400671

Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension.

Zhi-Cheng Jing1, Xi-Qi Xu, Zhi-Yan Han, Yan Wu, Ke-Wu Deng, Hao Wang, Zeng-Wu Wang, Xian-Sheng Cheng, Bo Xu, Sheng-Shou Hu, Ru-Tai Hui, Yue-Jin Yang.   

Abstract

BACKGROUND: To evaluate the clinical features and survival data of patients with idiopathic pulmonary arterial hypertension (PAH) and familial PAH in Chinese patients.
METHODS: Seventy-two patients with idiopathic PAH and familial PAH were enrolled in the study from 1999 to 2004 and were classified into two groups according to World Health Organization (WHO) functional class (I/II and III/IV). Clinical and hemodynamic data were recorded.
RESULTS: The mean age of the 72 patients was 35.9 years with female patient/male patient ratio of 2.4:1. A significant difference was identified in the clinical presentation between two WHO functional class groups at baseline. Echocardiography showed a mean pulmonary systolic pressure of 98 mm Hg. Left ventricular end-diastolic diameter was significantly smaller in the group of patients in WHO functional class III/IV than in those in class I/II group. After follow-up for a mean (+/- SD) duration of 40.1 +/- 20.0 months, the survival rates at 1, 2, 3, and 5 years were 68.0%, 56.9%, 38.9%, and 20.8%, respectively. A significant difference was identified in survival rate between the class I/II and class III/IV groups (p = 0.02 [log rank test]).
CONCLUSIONS: The baseline characteristics and survival rates of our cohort study are close to those of the National Institutes of Health Registry in the 1980s, and the 1-year survival rate is obviously lower for patients in this registry than for those in the French registry between 2002 to 2003. Lack of effective treatment was the main cause of poor survival in this study. Our results support the need of an appropriate treatment strategy for this devastating disease in China.

Entities:  

Mesh:

Year:  2007        PMID: 17400671     DOI: 10.1378/chest.06-2913

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  68 in total

Review 1.  Definition, epidemiology and registries of pulmonary hypertension.

Authors:  R Awdish; H Cajigas
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Pulmonary hypertension as an independent predictor of cardiovascular mortality and events in hemodialysis patients.

Authors:  Zhilian Li; Shuangxin Liu; Xinling Liang; Wenjian Wang; Hongwen Fei; Penghua Hu; Yuanhan Chen; Lixia Xu; Ruizhao Li; Wei Shi
Journal:  Int Urol Nephrol       Date:  2013-06-21       Impact factor: 2.370

Review 3.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

4.  The specialty of pulmonary vascular medicine in China: historical development and future directions.

Authors:  Hua Luo; Jingwen Li
Journal:  Cardiovasc Diagn Ther       Date:  2012-09

5.  Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Daniele G Costa; Luiza V P Mendes; Ananssa M S Silva; Sabrina T Martinez; Margarete M Trachez; Valéria do M N Cunha; Tadeu L Montagnoli; Aline G M Fraga; Hao Wang; Leanne Groban; Carlos A M Fraga; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-08-10       Impact factor: 6.053

6.  Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.

Authors:  Masaru Hatano; Hidehiro Yamada; Keiichi Fukuda; Koichiro Yoshioka; Masanori Funauchi; Masataka Kuwana; Masataka Sata; Mitsugu Taniguchi; Norifumi Nakanishi; Takefumi Saito; Tsutomu Saji; Shigetake Sasayama
Journal:  Heart Vessels       Date:  2014-07-16       Impact factor: 2.037

Review 7.  Cardiopulmonary exercise testing in the assessment of pulmonary hypertension.

Authors:  Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 8.  Epidemiology and treatment of pulmonary arterial hypertension.

Authors:  Edmund M T Lau; Eleni Giannoulatou; David S Celermajer; Marc Humbert
Journal:  Nat Rev Cardiol       Date:  2017-06-08       Impact factor: 32.419

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 10.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.